Sentinel, a project within the Penta-Euripides² Eureka Clusters, was a collaborative research initiative dedicated to innovating patient monitoring. While vital signs are continuously tracked, biomarkers such as glucose and lactate are still measured manually through invasive blood draws. Sentinel aimed to close these gaps in hospitals’ early warning systems (EWS) by developing a wearable device capable of semi-continuous hybrid sensing, supported by integrated electronics, algorithms, manufacturing technology and verified prototypes.
By ensuring semi-continuous, non-invasive monitoring in an autonomous and hybrid manner, Sentinel has the potential to decrease complications and mortality, reduce the number of permanent disabilities, and thereby improve the quality of life for patients while reducing healthcare costs.
The consortium brought together a diverse group of academic institutions, technology companies and hospitals, including Philips Electronics Nederland BV, AZ Turnhout, Catharina Ziekenhuis, Eindhoven University of Technology, Etteplan, Jobst Technologies GmbH, Micronit BV, Sapienza University – Dept. Mech. Aerosp. Eng and Verhaert. Verhaert’s multidisciplinary expertise in adhesives, electronics, and especially Verhaert Digital’s experience in data acquisition and AI-powered data labeling played a key role in helping achieve this ambitious goal.



